{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:07:02Z","timestamp":1789614422948,"version":"build-2803163510"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11060-022-04118-0","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T17:05:53Z","timestamp":1661274353000},"page":"79-100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Intrathecal therapy for the management of leptomeningeal metastatic disease: a scoping review of the current literature and ongoing clinical trials"],"prefix":"10.1007","volume":"160","author":[{"given":"Paolo","family":"Palmisciano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andie","family":"Conching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morana","family":"Vojnic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy S.","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"4118_CR1","doi-asserted-by":"publisher","first-page":"116706","DOI":"10.1016\/j.jns.2020.116706","volume":"411","author":"JP Thakkar","year":"2020","unstructured":"Thakkar JP, Kumthekar P, Dixit KS et al (2020) Leptomeningeal metastasis from solid tumors. J Neurol Sci 411:116706. https:\/\/doi.org\/10.1016\/j.jns.2020.116706","journal-title":"J Neurol Sci"},{"key":"4118_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/ana.410380111","volume":"38","author":"RJ Freilich","year":"1995","unstructured":"Freilich RJ, Krol G, Deangelis LM (1995) Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 38:51\u201357. https:\/\/doi.org\/10.1002\/ana.410380111","journal-title":"Ann Neurol"},{"key":"4118_CR3","doi-asserted-by":"publisher","first-page":"v86","DOI":"10.1093\/noajnl\/vdab108","volume":"3","author":"U Sener","year":"2021","unstructured":"Sener U, Kumthekar P, Boire A (2021) Advances in the diagnosis, evaluation, and management of leptomeningeal disease. Neuro-Oncol Adv 3:v86\u2013v95. https:\/\/doi.org\/10.1093\/noajnl\/vdab108","journal-title":"Neuro-Oncol Adv"},{"key":"4118_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cncr.30911","volume":"124","author":"N Wang","year":"2018","unstructured":"Wang N, Bertalan MS, Brastianos PK (2018) Leptomeningeal metastasis from systemic cancer: review and update on management. Cancer 124:21\u201335. https:\/\/doi.org\/10.1002\/cncr.30911","journal-title":"Cancer"},{"key":"4118_CR5","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S1470-2045(10)70034-6","volume":"11","author":"P Beauchesne","year":"2010","unstructured":"Beauchesne P (2010) Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol 11:871\u2013879. https:\/\/doi.org\/10.1016\/S1470-2045(10)70034-6","journal-title":"Lancet Oncol"},{"key":"4118_CR6","doi-asserted-by":"publisher","first-page":"114338","DOI":"10.1016\/j.addr.2022.114338","volume":"186","author":"M Khang","year":"2022","unstructured":"Khang M, Bindra RS, Mark Saltzman W (2022) Intrathecal delivery and its applications in leptomeningeal disease. Adv Drug Deliv Rev 186:114338. https:\/\/doi.org\/10.1016\/j.addr.2022.114338","journal-title":"Adv Drug Deliv Rev"},{"key":"4118_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11060-007-9511-3","volume":"87","author":"N Shinoura","year":"2008","unstructured":"Shinoura N, Tabei Y, Yamada R et al (2008) Continuous intrathecal treatment with methotrexate via subcutaneous port: implication for leptomeningeal dissemination of malignant tumors. J Neuro-Oncol 87:309\u2013316. https:\/\/doi.org\/10.1007\/s11060-007-9511-3","journal-title":"J Neuro-Oncol"},{"key":"4118_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1159\/000120013","volume":"8","author":"MS Edwards","year":"1981","unstructured":"Edwards MS, Levin VA, Seager ML, Wilson CB (1981) Intrathecal chemotherapy for leptomeningeal dissemination of medulloblastoma. Pediatr Neurosurg 8:444\u2013451. https:\/\/doi.org\/10.1159\/000120013","journal-title":"Pediatr Neurosurg"},{"key":"4118_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s11060-014-1486-2","volume":"119","author":"BJ Scott","year":"2014","unstructured":"Scott BJ, van Vugt VA, Rush T et al (2014) Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. J Neuro-Oncol 119:361\u2013368. https:\/\/doi.org\/10.1007\/s11060-014-1486-2","journal-title":"J Neuro-Oncol"},{"key":"4118_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2018.00509","volume":"8","author":"M de Oca","year":"2018","unstructured":"de Oca M, Delgado M, Cacho D\u00edaz B, Santos Zambrano J et al (2018) The comparative treatment of intraventricular chemotherapy by ommaya reservoir vs. lumbar puncture in patients with leptomeningeal carcinomatosis. Front Oncol 8:1\u20137. https:\/\/doi.org\/10.3389\/fonc.2018.00509","journal-title":"Front Oncol"},{"key":"4118_CR11","doi-asserted-by":"publisher","first-page":"100150","DOI":"10.1016\/j.esmoop.2021.100150","volume":"6","author":"M Carausu","year":"2021","unstructured":"Carausu M, Carton M, Darlix A et al (2021) Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database. ESMO Open 6:100150. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100150","journal-title":"ESMO Open"},{"key":"4118_CR12","doi-asserted-by":"publisher","first-page":"175883592093795","DOI":"10.1177\/1758835920937953","volume":"12","author":"Z Pan","year":"2020","unstructured":"Pan Z, Yang G, He H et al (2020) Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: a phase I\/II study. Ther Adv Med Oncol 12:1758835920937953. https:\/\/doi.org\/10.1177\/1758835920937953","journal-title":"Ther Adv Med Oncol"},{"key":"4118_CR13","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/jjco\/hyab155","volume":"51","author":"L Hou","year":"2021","unstructured":"Hou L, Han W, Jin J et al (2021) Clinical efficacy and safety of different doses of intrathecal methotrexate in the treatment of leptomeningeal carcinomatosis: a prospective and single-arm study. Jpn J Clin Oncol 51:1715\u20131722. https:\/\/doi.org\/10.1093\/jjco\/hyab155","journal-title":"Jpn J Clin Oncol"},{"key":"4118_CR14","doi-asserted-by":"publisher","first-page":"e000283","DOI":"10.1136\/esmoopen-2017-000283","volume":"3","author":"IC Glitza","year":"2018","unstructured":"Glitza IC, Rohlfs M, Guha-Thakurta N et al (2018) Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open 3:e000283. https:\/\/doi.org\/10.1136\/esmoopen-2017-000283","journal-title":"ESMO Open"},{"key":"4118_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejca.2018.02.032","volume":"95","author":"C Bonneau","year":"2018","unstructured":"Bonneau C, Paintaud G, Tr\u00e9dan O et al (2018) Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. Eur J Cancer 95:75\u201384. https:\/\/doi.org\/10.1016\/j.ejca.2018.02.032","journal-title":"Eur J Cancer"},{"key":"4118_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10549-018-4684-3","volume":"169","author":"NB Figura","year":"2018","unstructured":"Figura NB, Long W, Yu M et al (2018) Intrathecal trastuzumab in the management of HER2 + breast leptomeningeal disease: a single institution experience. Breast Cancer Res Treat 169:391\u2013396. https:\/\/doi.org\/10.1007\/s10549-018-4684-3","journal-title":"Breast Cancer Res Treat"},{"key":"4118_CR17","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s10549-019-05170-7","volume":"175","author":"NB Figura","year":"2019","unstructured":"Figura NB, Rizk VT, Mohammadi H et al (2019) Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy. Breast Cancer Res Treat 175:781\u2013788. https:\/\/doi.org\/10.1007\/s10549-019-05170-7","journal-title":"Breast Cancer Res Treat"},{"key":"4118_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.currproblcancer.2017.07.001","volume":"41","author":"Y-C Lee","year":"2017","unstructured":"Lee Y-C, Hsieh C-C, Chuang J-P, Li C-Y (2017) The necessity of intrathecal chemotherapy for the treatment of breast cancer patients with leptomeningeal metastasis: a systematic review and pooled analysis. Curr Probl Cancer 41:355\u2013370. https:\/\/doi.org\/10.1016\/j.currproblcancer.2017.07.001","journal-title":"Curr Probl Cancer"},{"key":"4118_CR19","doi-asserted-by":"publisher","first-page":"102046","DOI":"10.1016\/j.ctrv.2020.102046","volume":"88","author":"F Zagouri","year":"2020","unstructured":"Zagouri F, Zoumpourlis P, Le Rhun E et al (2020) Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: a metanalysis with meta-regression. Cancer Treat Rev 88:102046. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102046","journal-title":"Cancer Treat Rev"},{"key":"4118_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169:467\u2013473. https:\/\/doi.org\/10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"4118_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/neuonc\/now183","volume":"19","author":"M Chamberlain","year":"2016","unstructured":"Chamberlain M, Junck L, Brandsma D et al (2016) Leptomeningeal metastases: a RANO proposal for response criteria. Neuro-Oncology 19:183. https:\/\/doi.org\/10.1093\/neuonc\/now183","journal-title":"Neuro-Oncology"},{"key":"4118_CR22","unstructured":"Howick J, Chalmers I, Glasziou P, et al (2011) Explanation of the 2011 oxford centre for evidence-based medicine (OCEBM) Levels of evidence (Background Document). In: Oxford Cent. Evidence-Based Med. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence"},{"key":"4118_CR23","volume-title":"JBI manual for evidence synthesis","author":"S Moola","year":"2020","unstructured":"Moola S, Munn Z, Tufanaru C et al (2020) Chapter 7: systematic reviews of etiology and risk. In: Aromataris E, Munn Z (eds) JBI manual for evidence synthesis. JBI, Adelaide"},{"key":"4118_CR24","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/BF00292408","volume":"23","author":"VA Levin","year":"1989","unstructured":"Levin VA, Chamberlain M, Silver P et al (1989) Phase I\/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia. Cancer Chemother Pharmacol 23:301\u2013307. https:\/\/doi.org\/10.1007\/BF00292408","journal-title":"Cancer Chemother Pharmacol"},{"key":"4118_CR25","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1200\/JCO.1998.16.4.1561","volume":"16","author":"MJ Glantz","year":"1998","unstructured":"Glantz MJ, Cole BF, Recht L et al (1998) High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol 16:1561\u20131567. https:\/\/doi.org\/10.1200\/JCO.1998.16.4.1561","journal-title":"J Clin Oncol"},{"key":"4118_CR26","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1347::AID-CNCR34>3.0.CO;2-M","volume":"86","author":"TF Witham","year":"1999","unstructured":"Witham TF, Fukui MB, Meltzer CC et al (1999) Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramide for ependymal or leptomeningeal gliomatosis. Cancer 86:1347\u20131353. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19991001)86:7%3c1347::AID-CNCR34%3e3.0.CO;2-M","journal-title":"Cancer"},{"key":"4118_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s002800000173","volume":"46","author":"FJ Esteva","year":"2000","unstructured":"Esteva FJ, Soh L-T, Holmes FA et al (2000) Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemother Pharmacol 46:382\u2013386. https:\/\/doi.org\/10.1007\/s002800000173","journal-title":"Cancer Chemother Pharmacol"},{"key":"4118_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00006123-200007000-00011","volume":"47","author":"DI Sandberg","year":"2000","unstructured":"Sandberg DI, Bilsky MH, Souweidane MM et al (2000) Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 47:49\u201355. https:\/\/doi.org\/10.1097\/00006123-200007000-00011","journal-title":"Neurosurgery"},{"key":"4118_CR29","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/jjco\/hyg118","volume":"33","author":"D-Y Kim","year":"2003","unstructured":"Kim D-Y (2003) Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol 33:608\u2013612. https:\/\/doi.org\/10.1093\/jjco\/hyg118","journal-title":"Jpn J Clin Oncol"},{"key":"4118_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00381-007-0538-8","volume":"24","author":"J Yoshimura","year":"2008","unstructured":"Yoshimura J, Nishiyama K, Mori H et al (2008) Intrathecal chemotherapy for refractory disseminated medulloblastoma. Child\u2019s Nerv Syst 24:581\u2013585. https:\/\/doi.org\/10.1007\/s00381-007-0538-8","journal-title":"Child\u2019s Nerv Syst"},{"key":"4118_CR31","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11060-009-9940-2","volume":"95","author":"F Clatot","year":"2009","unstructured":"Clatot F, Philippin-Lauridant G, Ouvrier M-J et al (2009) Clinical improvement and survival in breast cancer leptomeningeal metastasis correlate with the cytologic response to intrathecal chemotherapy. J Neuro-Oncol 95:421\u2013426. https:\/\/doi.org\/10.1007\/s11060-009-9940-2","journal-title":"J Neuro-Oncol"},{"key":"4118_CR32","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/j.1365-2141.2010.08238.x","volume":"150","author":"J-M Calvo-Villas","year":"2010","unstructured":"Calvo-Villas J-M, Fern\u00e1ndez JA, De La Fuente I et al (2010) Intrathecal liposomal cytarabine for treatment of leptomeningeal involvement in transformed (Richter\u2019s syndrome) and non-transformed B-cell chronic lymphocytic leukaemia in Spain: a report of seven cases. Br J Haematol 150:618\u2013620. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08238.x","journal-title":"Br J Haematol"},{"key":"4118_CR33","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00701-011-1086-2","volume":"153","author":"H-S Gwak","year":"2011","unstructured":"Gwak H-S, Lee C-H, Yang HS et al (2011) Chemoport with a non-collapsible chamber as a replacement for an Ommaya reservoir in the treatment of leptomeningeal carcinomatosis. Acta Neurochir 153:1971\u20131978. https:\/\/doi.org\/10.1007\/s00701-011-1086-2","journal-title":"Acta Neurochir"},{"key":"4118_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11060-012-0880-x","volume":"109","author":"MC Chamberlain","year":"2012","unstructured":"Chamberlain MC (2012) Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. J Neuro-Oncol 109:143\u2013148. https:\/\/doi.org\/10.1007\/s11060-012-0880-x","journal-title":"J Neuro-Oncol"},{"key":"4118_CR35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11060-013-1244-x","volume":"115","author":"A Comte","year":"2013","unstructured":"Comte A, Jdid W, Guilhaume MN et al (2013) Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa. J Neuro-Oncol 115:445\u2013452. https:\/\/doi.org\/10.1007\/s11060-013-1244-x","journal-title":"J Neuro-Oncol"},{"key":"4118_CR36","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11060-013-1241-0","volume":"115","author":"JP Fusco","year":"2013","unstructured":"Fusco JP, Casta\u00f1\u00f3n E, Carranza OE et al (2013) Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: a retrospective cohort study. J Neuro-Oncol 115:429\u2013435. https:\/\/doi.org\/10.1007\/s11060-013-1241-0","journal-title":"J Neuro-Oncol"},{"key":"4118_CR37","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1007\/s10072-013-1358-0","volume":"34","author":"P Gaviani","year":"2013","unstructured":"Gaviani P, Corsini E, Salmaggi A et al (2013) Liposomal cytarabine in neoplastic meningitis from primary brain tumors: a single institutional experience. Neurol Sci 34:2151\u20132157. https:\/\/doi.org\/10.1007\/s10072-013-1358-0","journal-title":"Neurol Sci"},{"key":"4118_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clbc.2014.07.004","volume":"15","author":"A Niwi\u0144ska","year":"2015","unstructured":"Niwi\u0144ska A, Rudnicka H, Murawska M (2015) breast cancer leptomeningeal metastasis: the results of combined treatment and the comparison of methotrexate and liposomal cytarabine as intra-cerebrospinal fluid chemotherapy. Clin Breast Cancer 15:66\u201372. https:\/\/doi.org\/10.1016\/j.clbc.2014.07.004","journal-title":"Clin Breast Cancer"},{"key":"4118_CR39","first-page":"5631","volume":"35","author":"K-M Cho","year":"2015","unstructured":"Cho K-M, Kim YJ, Kim SH et al (2015) Salvage treatment with intracerebrospinal fluid thiotepa in patients with leptomeningeal metastasis after failure of methotrexate-based treatment. Anticancer Res 35:5631\u20135638","journal-title":"Anticancer Res"},{"key":"4118_CR40","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1002\/ijc.30214","volume":"139","author":"Z Pan","year":"2016","unstructured":"Pan Z, Yang G, He H et al (2016) Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: a prospective and single-arm study. Int J Cancer 139:1864\u20131872. https:\/\/doi.org\/10.1002\/ijc.30214","journal-title":"Int J Cancer"},{"key":"4118_CR41","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1590\/0004-282x-anp-2020-0554","volume":"79","author":"S Comlek","year":"2021","unstructured":"Comlek S, Saglam S (2021) A new approach for leptomeningeal metastases: chemotherapy administered through lumbar intrathecal port. Arq Neuropsiquiatr 79:816\u2013823. https:\/\/doi.org\/10.1590\/0004-282x-anp-2020-0554","journal-title":"Arq Neuropsiquiatr"},{"key":"4118_CR42","doi-asserted-by":"publisher","first-page":"7935","DOI":"10.1002\/cam4.3422","volume":"9","author":"KA Jaeckle","year":"2020","unstructured":"Jaeckle KA, Dixon JG, Anderson SK et al (2020) Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases. Cancer Med 9:7935\u20137942. https:\/\/doi.org\/10.1002\/cam4.3422","journal-title":"Cancer Med"},{"key":"4118_CR43","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3340\/jkns.2020.0300","volume":"64","author":"J-W Kwon","year":"2021","unstructured":"Kwon J-W, Shim Y, Gwak H-S et al (2021) Cerebrospinal fluid profiles and their changes after intraventricular chemotherapy as prognostic or predictive markers for patients with leptomeningeal carcinomatosis. J Korean Neurosurg Soc 64:631\u2013643. https:\/\/doi.org\/10.3340\/jkns.2020.0300","journal-title":"J Korean Neurosurg Soc"},{"key":"4118_CR44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4103\/ijc.IJC_730_18","volume":"58","author":"VK Srinivasalu","year":"2018","unstructured":"Srinivasalu VK, Subramaniam N, Philip A et al (2018) Triple intrathecal chemotherapy for leptomeningeal carcinomatosis in solid tumors: treatment outcomes, response and their determinants. Indian J Cancer 58:84\u201390. https:\/\/doi.org\/10.4103\/ijc.IJC_730_18","journal-title":"Indian J Cancer"},{"key":"4118_CR45","doi-asserted-by":"publisher","first-page":"153303382210784","DOI":"10.1177\/15330338221078429","volume":"21","author":"D Geng","year":"2022","unstructured":"Geng D, Guo Q, Huang S et al (2022) A retrospective study of intrathecal pemetrexed combined with systemic therapy for leptomeningeal metastasis of lung cancer. Technol Cancer Res Treat 21:153303382210784. https:\/\/doi.org\/10.1177\/15330338221078429","journal-title":"Technol Cancer Res Treat"},{"key":"4118_CR46","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/BF02327385","volume":"6","author":"WT Sause","year":"1988","unstructured":"Sause WT, Crowley J, Eyre HJ et al (1988) Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases \u2014a southwest oncology group study. J Neuro-Oncol 6:107\u2013112. https:\/\/doi.org\/10.1007\/BF02327385","journal-title":"J Neuro-Oncol"},{"key":"4118_CR47","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1200\/JCO.1986.4.1.68","volume":"4","author":"L Giannone","year":"1986","unstructured":"Giannone L, Greco FA, Hainsworth JD (1986) Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 4:68\u201373. https:\/\/doi.org\/10.1200\/JCO.1986.4.1.68","journal-title":"J Clin Oncol"},{"key":"4118_CR48","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1215\/15228517-2007-059","volume":"10","author":"MD Groves","year":"2008","unstructured":"Groves MD, Glantz MJ, Chamberlain MC et al (2008) A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro-Oncology 10:208\u2013215. https:\/\/doi.org\/10.1215\/15228517-2007-059","journal-title":"Neuro-Oncology"},{"key":"4118_CR49","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/cncr.24921","volume":"116","author":"MJ Glantz","year":"2010","unstructured":"Glantz MJ, Van Horn A, Fisher R, Chamberlain MC (2010) Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer 116:1947\u20131952. https:\/\/doi.org\/10.1002\/cncr.24921","journal-title":"Cancer"},{"key":"4118_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00838","author":"Z Pan","year":"2019","unstructured":"Pan Z, Yang G, Cui J et al (2019) A pilot phase 1 study of intrathecal pemetrexed for refractory leptomeningeal metastases from non-small-cell lung cancer. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2019.00838","journal-title":"Front Oncol"},{"key":"4118_CR51","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.jtho.2021.04.018","volume":"16","author":"C Fan","year":"2021","unstructured":"Fan C, Zhao Q, Li L et al (2021) Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase inhibitor-failed leptomeningeal metastases from EGFR-mutant NSCLC\u2014a prospective, open-label, single-arm phase 1\/2 clinical trial (unique identifier: chi. J Thorac Oncol 16:1359\u20131368. https:\/\/doi.org\/10.1016\/j.jtho.2021.04.018","journal-title":"J Thorac Oncol"},{"key":"4118_CR52","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1200\/JCO.1987.5.10.1655","volume":"5","author":"RN Hitchins","year":"1987","unstructured":"Hitchins RN, Bell DR, Woods RL, Levi JA (1987) A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 5:1655\u20131662. https:\/\/doi.org\/10.1200\/JCO.1987.5.10.1655","journal-title":"J Clin Oncol"},{"key":"4118_CR53","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1200\/JCO.1993.11.3.561","volume":"11","author":"SA Grossman","year":"1993","unstructured":"Grossman SA, Finkelstein DM, Ruckdeschel JC et al (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern cooperative oncology group. J Clin Oncol 11:561\u2013569. https:\/\/doi.org\/10.1200\/JCO.1993.11.3.561","journal-title":"J Clin Oncol"},{"key":"4118_CR54","first-page":"3394","volume":"5","author":"MJ Glantz","year":"1999","unstructured":"Glantz MJ, Jaeckle KA, Chamberlain MC et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:3394\u20133402","journal-title":"Clin Cancer Res"},{"key":"4118_CR55","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1016\/j.ejca.2004.08.012","volume":"40","author":"W Boogerd","year":"2004","unstructured":"Boogerd W, van den Bent MJ, Koehler PJ et al (2004) The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 40:2726\u20132733. https:\/\/doi.org\/10.1016\/j.ejca.2004.08.012","journal-title":"Eur J Cancer"},{"key":"4118_CR56","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/neuonc\/noz201","volume":"22","author":"E Le Rhun","year":"2020","unstructured":"Le Rhun E, Wallet J, Mailliez A et al (2020) Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. Neuro-Oncology 22:524\u2013538. https:\/\/doi.org\/10.1093\/neuonc\/noz201","journal-title":"Neuro-Oncology"},{"key":"4118_CR57","unstructured":"Pan Z, Yang G (2022) Phase I\/II Clinical trial of intrathecal pemetrexed as first line intrathecal chemotherapy in patients with leptomeningeal metastasis (NCT05289908). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05289908"},{"key":"4118_CR58","unstructured":"Tabatabai G (2022) Intrathecal application of PD1 antibody in metastatic solid tumors with leptomeningeal disease (IT-PD1\/NOA 26) (IT-PD1) (NCT05112549). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05112549"},{"key":"4118_CR59","unstructured":"Ahmed K (2022) Radiation therapy followed by intrathecal trastuzumab\/pertuzumab in HER2 + breast leptomeningeal disease (NCT04588545). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04588545"},{"key":"4118_CR60","unstructured":"Glitza IC (2022) Intravenous and intrathecal nivolumab in treating patients with leptomeningeal disease (NCT03025256)"},{"key":"4118_CR61","doi-asserted-by":"publisher","first-page":"619","DOI":"10.21873\/anticanres.15519","volume":"42","author":"P Palmisciano","year":"2022","unstructured":"Palmisciano P, Sagoo NS, Kharbat AF et al (2022) Leptomeningeal metastases of the spine: a systematic review. Anticancer Res 42:619\u2013628","journal-title":"Anticancer Res"},{"key":"4118_CR62","doi-asserted-by":"publisher","first-page":"73312","DOI":"10.18632\/oncotarget.20272","volume":"8","author":"G Nayar","year":"2017","unstructured":"Nayar G, Ejikeme T, Chongsathidkiet P et al (2017) Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget 8:73312\u201373328","journal-title":"Oncotarget"},{"key":"4118_CR63","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.21873\/anticanres.15346","volume":"41","author":"P Palmisciano","year":"2021","unstructured":"Palmisciano P, Haider AS, Nwagwu CD et al (2021) The role of immune checkpoint inhibitors in leptomeningeal disease: a systematic review. Anticancer Res 41:5333\u20135342","journal-title":"Anticancer Res"},{"key":"4118_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2019.01224","volume":"9","author":"SM Buszek","year":"2019","unstructured":"Buszek SM, Chung C (2019) Radiotherapy in leptomeningeal disease: a systematic review of randomized and non-randomized trials. Front Oncol 9:1\u201315. https:\/\/doi.org\/10.3389\/fonc.2019.01224","journal-title":"Front Oncol"},{"issue":"3\u20134","key":"4118_CR65","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/BF02792160","volume":"51","author":"A Bier","year":"1899","unstructured":"Bier A (1899) Versuche \u00fcber cocainisirung des r\u00fcckenmarkes. Dtsch Zeitschrift f\u00fcr Chir 51(3\u20134):361\u2013369","journal-title":"Dtsch Zeitschrift f\u00fcr Chir"},{"key":"4118_CR66","doi-asserted-by":"publisher","first-page":"E281","DOI":"10.1093\/neuros\/nyaa095","volume":"87","author":"E Aquilanti","year":"2020","unstructured":"Aquilanti E, Brastianos PK (2020) Immune checkpoint inhibitors for brain metastases: a primer for neurosurgeons. Neurosurgery 87:E281\u2013E288. https:\/\/doi.org\/10.1093\/neuros\/nyaa095","journal-title":"Neurosurgery"},{"key":"4118_CR67","doi-asserted-by":"publisher","first-page":"23548","DOI":"10.1038\/s41598-021-02903-x","volume":"11","author":"A Thulin","year":"2021","unstructured":"Thulin A, Andersson C, Werner R\u00f6nnerman E et al (2021) Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors. Sci Rep 11:23548. https:\/\/doi.org\/10.1038\/s41598-021-02903-x","journal-title":"Sci Rep"},{"key":"4118_CR68","unstructured":"Brastianos PK (2022) Genetic testing in guiding treatment for patients with brain metastases (NCT03994796)"},{"key":"4118_CR69","unstructured":"Ho C CSF (2022) Analysis in EGFR mutant non-small cell lung cancer with leptomeningeal disease (NCT05257967). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05257967"},{"key":"4118_CR70","unstructured":"Kumthekar PA (2022) Therapy treatment response trial in patients with leptomeningeal metastases ((LM) using CNSide (FORESEE) (NCT05414123)"},{"key":"4118_CR71","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","volume":"5","author":"PK Brastianos","year":"2015","unstructured":"Brastianos PK, Carter SL, Santagata S et al (2015) Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 5:1164\u20131177. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0369","journal-title":"Cancer Discov"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04118-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-022-04118-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-022-04118-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T20:24:16Z","timestamp":1667247856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-022-04118-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["4118"],"URL":"https:\/\/doi.org\/10.1007\/s11060-022-04118-0","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,23]]},"assertion":[{"value":"29 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"As this is a literature review, ethics approval is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As this is a literature review and no original data from new patients were collected, consent to participate is not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"As this is a literature review and no original data from new patients were collected, consent for publication is not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}